Interferon-alpha as an immunotherapeutic protein.
Interferon-alpha (IFN-alpha) has proven to be a clinically effective antiviral and antineoplastic therapeutic drug for more than 16 years. During this time, evidence from in vitro laboratory studies and the clinical arena has supported the concept that IFN-alpha is an immunotherapeutic drug. By regulating a diverse set of cytokines and their receptors, IFN-alpha is uniquely positioned to prime the host immune response and provide an effective antineoplastic- and antiviral-immune response. IFN-alpha stimulates the innate cell-mediated response and then participates in the transition of the initial host innate response into an effective adaptive-immune response. IFN-alpha also drives the adaptive cell-mediated CD8+ T-cell response and helps to maintain a CD4+ Th1-cell population balance for an effective antineoplastic and antiviral host defense. This review will describe the current state of knowledge of IFN-alpha as an immunoregulatory protein and address specific issues of IFN-alpha as an immunotherapeutic for antineoplastic and antiviral diseases.
Brassard
Diana L
DL
Bioanalytical Development, Schering-Plough Research Institute, Union, New Jersey 07083, USA.
Grace
Michael J
MJ
Bordens
Ronald W
RW
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D016898:Interferon-alpha